# First-in-Human Study of BCX9930 in Healthy Volunteers and Patients With PNH

> **NCT04330534** · PHASE1,PHASE2 · COMPLETED · sponsor: **BioCryst Pharmaceuticals** · enrollment: 168 (actual)

## Conditions studied

- Paroxysmal Nocturnal Hemoglobinuria

## Interventions

- **DRUG:** BCX9930
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04330534
- **Lead sponsor:** BioCryst Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-03-03
- **Primary completion:** 2020-11-11
- **Final completion:** 2021-01-25
- **Target enrollment:** 168 (ACTUAL)
- **Last updated:** 2022-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04330534

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04330534, "First-in-Human Study of BCX9930 in Healthy Volunteers and Patients With PNH". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04330534. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*